3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
12
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Advanced Solid Tumors
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
3
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
mCRPC
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Recurrent Squamous Cell Lung Carcinoma
1
Recurrence
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Hereditary Sensory and Autonomic Neuropathies
1
Fanconi Anemia, Complementation Group D1
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Adenocarcinoma
1
Advanced Solid Tumor
1
Advanced Ovarian Cancer
1
Interventions
pembrolizumab
26
atezolizumab
14
Nivolumab
13
Gemcitabine
13
Cisplatin
10
Docetaxel
8
Carboplatin
8
avelumab
7
Mitomycin
7
epacadostat
4
cabozantinib
4
Ipilimumab
4
pemigatinib
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Bevacizumab
3
vofatamab
2
rucaparib
2
lenvatinib
2
enfortumab vedotin
2
durvalumab
2
cabazitaxel
2
bempegaldesleukin
2
Standard of Care
2
Rogaratinib
2
Ramucirumab
2
Radiation
2
Platinum
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Transitional Cell
×
talazoparib
×
Clear all
No trials found.